Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Signs Contract with Takeda for Protein Biomarker Research

Premium

This story originally ran on March 30.

Proteome Sciences said this week it has closed a second research contract with drugmaker Takeda Pharmaceuticals for use of the company's PS Biomarker Services.

Under the agreement, Proteome Sciences will provide Takeda with mass spec-based assays for the discovery and validation of protein biomarkers tied to various undisclosed diseases.

The contract follows on a 2009 agreement between the companies, under which Proteome Sciences has used its isobaric Tandem Mass Tag reagents for preclinical protein biomarker research.

The deal is the latest of several contracts for pharma work the company has signed in recent months.

In February it announced that had signed with drugmaker Eisai to measure protein biomarkers tied to Alzheimer's disease (PM 02/04/2011). That contract called for Proteome Sciences to quantify in human samples levels of the nine proteins in its AD-TMT-SRM assay, marking the first commercial contract the company signed for use of the assay, which it introduced this summer.

In November it inked a deal with Irish pharmaceutical services firm Icon to offer biomarker discovery and validation work in support of drug development efforts (PM 11/19/2010).

Financial and other terms of the Takeda agreement were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.